SCHEMBL6288889

SCHEMBL6288889

Cn1c(=O)c(Cc2ccc(F)c(F)c2)cc2nc(C(=O)O)sc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.39
S1PR1 P21453 2/20 0.36
S1PR3 Q99500 2/20 0.36
SCD O00767 1/20 0.36
MPO P05164 1/20 0.36
IGFBP5 P24593 1/20 0.36
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MAPK14 Q16539 1/20 0.35
CACNA1G O43497 2/20 0.34
CACNA1H O95180 2/20 0.34
CACNA1I Q9P0X4 2/20 0.34
LDHA P00338 1/20 0.33
LDHB P07195 1/20 0.33
PLA2G7 Q13093 1/20 0.33
NAMPT P43490 1/20 0.33
JAK2 O60674 1/20 0.33
ZAP70 P43403 1/20 0.33
SYK P43405 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288790 0.85 MAOB (0.48) MAOBSCDCACNA1GCACNA1HCACNA1I
SCHEMBL6289386 0.80 MAPK14 (0.36) S1PR1S1PR3SCDMPOKDM5A
SCHEMBL6292115 0.78 MMP13 (0.36) S1PR1S1PR3SCDMPOMAPK14
SCHEMBL6289395 0.76 KDM5A (0.40) MPOIGFBP5KDM5AKDM5BMAPK14
SCHEMBL6700331 0.73 TRPC5 (0.38) MAOBSCD
SCHEMBL6289340 0.72 MAPK14 (0.39) S1PR1S1PR3MPOKDM5AKDM5B
SCHEMBL6485426 0.71 P2RY14 (0.36) MAOBS1PR1S1PR3SCDMPO
SCHEMBL6292190 0.71 MAPT (0.45) S1PR3SCDCACNA1GCACNA1HCACNA1I
SCHEMBL6699400 0.69 PTGS1 (0.40)
SCHEMBL6289365 0.69 ADRA1A (0.34) MAPK14PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US claimed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US claimed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MAOB 382/4885S1PR1 1241/4885S1PR3 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.